Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACRS 
Aclaris Therapeutics Inc (ACRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ACRS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.86
1 Year Target Price $7.86
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 53.72% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.33M USD | Price to earnings Ratio - | 1Y Target Price 7.86 |
Price to earnings Ratio - | 1Y Target Price 7.86 | ||
Volume (30-day avg) 6 | Beta 0.29 | 52 Weeks Range 1.05 - 5.17 | Updated Date 09/16/2025 |
52 Weeks Range 1.05 - 5.17 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -951.49% |
Management Effectiveness
Return on Assets (TTM) -20.86% | Return on Equity (TTM) -101.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 92567825 | Price to Sales(TTM) 11.87 |
Enterprise Value 92567825 | Price to Sales(TTM) 11.87 | ||
Enterprise Value to Revenue 5.51 | Enterprise Value to EBITDA 0.28 | Shares Outstanding 108332000 | Shares Floating 72651919 |
Shares Outstanding 108332000 | Shares Floating 72651919 | ||
Percent Insiders 2.69 | Percent Institutions 86.19 |
Upturn AI SWOT
Aclaris Therapeutics Inc
Company Overview
History and Background
Aclaris Therapeutics, Inc. (ARRS) was founded in 2012. It is a biopharmaceutical company focusing on immuno-inflammatory diseases. The company has evolved through strategic acquisitions and development of novel therapies.
Core Business Areas
- Immuno-inflammatory Dermatology: Focuses on developing and commercializing therapies for immuno-inflammatory dermatological conditions like vitiligo, alopecia areata, and atopic dermatitis.
Leadership and Structure
The leadership team includes Neal Walker (CEO). The organizational structure consists of research, development, and commercial departments, with a board of directors providing oversight.
Top Products and Market Share
Key Offerings
- Zoryve (roflumilast) topical cream 0.3%: ZORYVE is a once-daily topical PDE4 inhibitor approved for the treatment of plaque psoriasis in patients 12 years of age and older. Revenue from this product is the primary source of income for Aclaris. Competitors include topical corticosteroids and other topical treatments like vitamin D analogs from companies like LEO Pharma and Amgen (AMGN).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically dermatology, is highly competitive, driven by innovation and demand for effective treatments for various skin conditions.
Positioning
Aclaris is positioned as a specialty pharmaceutical company focused on immuno-inflammatory diseases, seeking to address unmet needs in dermatology with innovative therapies.
Total Addressable Market (TAM)
The global psoriasis market size was estimated at USD 27.4 billion in 2023 and is expected to reach USD 41.2 billion by 2032. Aclaris is positioned to capture a portion of this TAM through the sales of Zoryve, and future products.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- FDA-approved product (ZORYVE)
- Experienced management team
Weaknesses
- Reliance on single product revenue
- Limited financial resources compared to larger competitors
- Dependence on successful commercialization of existing products
Opportunities
- Expansion into new indications
- Strategic partnerships and acquisitions
- Growth in the dermatology market
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Adverse events or safety concerns regarding products
Competitors and Market Share
Key Competitors
- LEO Pharma
- Amgen (AMGN)
- Incyte (INCY)
Competitive Landscape
Aclaris faces competition from larger pharmaceutical companies with more resources. Their competitive advantage lies in novel therapeutic approaches and niche market focus.
Major Acquisitions
Concert Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 560
- Strategic Rationale: To expand the company's pipeline of novel treatments for immuno-inflammatory diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the development and commercialization of key products, particularly ZORYVE.
Future Projections: Future projections are dependent on successful product launches and market penetration. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding the indications for ZORYVE and exploring new therapeutic targets.
Summary
Aclaris Therapeutics is a biopharmaceutical company with a focus on immuno-inflammatory diseases. Its FDA-approved product, ZORYVE, generates the primary revenue. The recent acquisition of Concert Pharmaceuticals will help to expand pipeline of novel treatments. The company faces challenges in scaling its commercial operations and competing with larger companies, but it also has opportunities to expand into new indications.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data is illustrative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclaris Therapeutics Inc
Exchange NASDAQ | Headquaters Wayne, PA, United States | ||
IPO Launch date 2015-10-07 | Co-Founder, CEO & Chairman Dr. Neal S. Walker D.O., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.aclaristx.com |
Full time employees 61 | Website https://www.aclaristx.com | ||
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.